- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Evolving NSCLC Landscape: Comparing Recent Updates in Neoadjuvant and Perioperative Immunotherapy
An expert comparison of recent data on neoadjuvant and perioperative immunotherapy in resectable early-stage NSCLC, including CheckMate 77T, CheckMate-816, and KEYNOTE-671.
EP: 1.CheckMate 77T: Perioperative Immunotherapy in Resectable NSCLC
EP: 2.Evolving NSCLC Landscape: Comparing Recent Updates in Neoadjuvant and Perioperative Immunotherapy
EP: 3.Updates in ALK+ NSCLC: ALINA Trial at ESMO 2023
EP: 4.Lessons from LIBRETTO-431 Trial in RET+ NSCLC
EP: 5.PAPILLON Trial Insights: ESMO 2023
EP: 6.Innovations Needed and Future Directions in Treatment of NSCLC
This is a video synopsis/summary of a Post Conference Perspectives involving Patrick Forde, MBBCh.
Forde notes there is no direct comparison yet between perioperative trials using neoadjuvant immunotherapy plus adjuvant therapy vs neoadjuvant therapy alone. However, cross-trial comparisons suggest comparable 2-year event-free survival rates around 60% to 65% between the shorter 3-cycle neoadjuvant regimen in CheckMate-816 (NCT02998528) and longer regimens in KEYNOTE-671 (NCT03425643) and CheckMate-77T (NCT04025879). Among patients without a pathologic complete response (pCR), there is a suggestion of better outcomes with adjuvant therapy, but it is not definitive yet. An update from CheckMate-816 found very high 3-year overall survival exceeding 95% in patients achieving a pCR, despite most having stage III disease, for which historically, outcomes were much worse.
Forde explains that historically, positive adjuvant chemotherapy trials led to a focus on postoperative therapy over the past 15 years. However, with immunotherapy, there may be greater benefit from neoadjuvant treatment with immune checkpoint inhibitors to stimulate the immune system while tumor is still present. Data from melanoma also support crucial benefit from the neoadjuvant setting. Consequently, there has been a shift toward neoadjuvant chemoimmunotherapy. This requires close collaboration between specialties and early tumor testing to ensure patients with targetable mutations receive appropriate therapy.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
December 3rd 2025The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.
Read More
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
